Phosphoinositide 3-kinase inhibitors, including idelalisib, overcome P-glycoprotein-mediated resistance to gemtuzumab ozogamicin in human acute myeloid leukemia cells

Gemtuzumab ozogamicin (GO) is a CD33 antibody-drug conjugate effective alone or in combination with other agents in a subset of patients with acute myeloid leukemia (AML). However, many patients do not benefit from GO. Though GO resistance is incompletely understood, previous studies have suggested that pro-survival signaling via AKT and activity of ABC transporters such as P-glycoprotein (Pgp) may contribute.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research